Aligos raises $92M in private placement of shares and warrants

Aligos Therapeutics, Inc.

Gross proceeds of $92.15M from sale of 31.4M shares, 81.1M pre-funded warrants, and 56.2M common warrants.
Combined price per share + common warrant is $0.8193; per pre-funded warrant + common warrant is $0.8192.
Common warrants have exercise price $0.7568 and expire Oct 25, 2030; pre-funded warrants have $0.0001 exercise price.
Closing occurred Oct 25, 2023; executives and directors entered lock-up agreements.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aligos Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors (the "Purchasers") valued at approximately $92,149,996 (effective 2023-10-23).

Action: entry
Agreement: equity purchase
Counterparty: certain investors (the "Purchasers")
Value: approximately $92,149,996
Effective: 2023-10-23

Exact text from the filing

On October 23, 2023, Aligos Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).

View on SEC.gov

Browse all material agreements →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-263158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.